Status:
COMPLETED
AZD2624 Multiple Ascending Dose Study in Japan
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Safety
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624
Eligibility Criteria
Inclusion
- Healthy young male Japanese volunteers
Exclusion
- Significant illness, as judged by the investigator, within 2 weeks of screening visit or Day 1
- Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit or Day 1
- Blood loss in excess of 200 mL within 30 days of screening visit or Day 1, in excess of 400 mL within 90 days of screening visit or Day 1, or in excess of 1200 mL within 1 year of screening visit or Day 1
- Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator at screening or pre first dose
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00696865
Start Date
May 1 2008
End Date
August 1 2008
Last Update
July 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Kanagawa, Japan